skip to main content

BI 456906, sponsored by Boehringer Ingelheim Ltd.

BI 456906, sponsored by Boehringer Ingelheim Ltd.

This study is a phase II, randomized, parallel group, multi-center, dose-finding study of subcutaneously administered BI 456906, compared with placebo and open-label semaglutide in patients with type 2 diabetes mellitus who have insufficient glycemic control despite diet, exercise, and metformin treatment.

If you would like to take part you will be invited to come to Research & Development trial clinic for a screen visit. This visit will take 1 hour to complete. If you’re eligible for the study, your participation in the trial will last approximately 23 weeks and require approximately 13 visits to the trial clinic. If you’re in one of the groups receiving the injection twice a week, you will have about 20 visits to the trial clinic. For your time and inconvenience related to taking part in this study, and to take account of any loss of earnings, the sponsor will pay the costs of £30 per visit (plus £10 if you’re assigned to group which need to come to clinic twice per week).

To take part you must meet the following criteria:

  • Participant is willing and able to give informed consent for participation in the study;

  • Participant is 18 years to 75 years of age on the day of signing informed consent;

  • Diagnosis of type 2 diabetes mellitus at least 6 months prior to informed consent;

  • Treatment with a stable dose of metformin >=1000mg/day for at least 3 months;

  • BMI 25kg/m2 -50kg/m2;

If you would like to take part or want more information please contact the study lead:

Study Contact: Qi Zheng


Page Comments